About heberprot-P
Heberprot-P is an innovative Cuban product containing recombinant human epidermal growth factor for peri- and intra-lesional infiltration; evidence reveals it accelerates healing of deep and complex ulcers, both ischemic and neuropathic, and reduces diabetes-related amputations. Clinical trials of Heberprot-P in patients with diabetic foot ulcers have shown that repeated local infiltration of this product can enhance healing of chronic wounds safely and efficaciously. As a result, Heberprot-P was registered in Cuba in 2006, and in 2007 was included in the National Basic Medications List and approved for marketing.
​
Heberprot-P is a unique therapy for the most complicated and recalcitrant chronic wounds usually associated with high amputation risk. Local injection in complex diabetic wounds has demonstrated a favorable risk-benefit ratio by speeding healing, reducing recurrences and attenuating amputation risk. Developed by a team of experts led by Dr. Jorge Berlanga Acosta from the Center for Genetic Engineering and Biotechnology (CIGB), Heberprot-P is an injectable medication used to treat advanced foot ulcers in diabetic patients by accelerating the healing process, thus reducing the risk of amputation in over 78% of cases.
The only one of its kind in the world, the product received the Gold Medal awarded by the World Intellectual Property Organization (WIPO) and offers a novel therapeutic solution to a condition which previously lacked effective treatments.
Heberprot-P has been used to help treat more than 250,000 people and is registered for use in 23 countries.
​
Amputations are on the rise in the United States. There were over 154,000 diabetes-related amputations that took place in the United States last year—2022--a 75% increase in just a decade. Diabetes is the single greatest factor in amputations—more than 60% of non-traumatic lower limb amputations happen in the diabetes population. An individual who has had an amputation has a worse chance of five-year survival than someone with coronary artery disease, breast cancer, and colorectal cancer.
Amputations in the United States are also substantially more prevalent among people of color. Quite simply, whether or not you have a limb amputated can come down to the color of your skin, how much money you make, and where you live.
